Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2018 Aug 25

PMID 30140295

Citations 10

Authors

Jia Liu

Ziqiang Li

Hua Liu

Xianhua Wang

Chunxiao Lv

Ruihua Wang

Deqin Zhang

Yan Li

Xi Du

Yanfen Li

Baohe Wang

Yuhong Huang

Affiliations

Soon will be listed here.

Abstract

Tangzhiqing tablet (TZQ) is derived from Tangzhiqing formula, which has been used to regulate glucose and lipid metabolism in China for hundreds of years. However, as a new Chinese patent medicine, its clinical indication is not clear. To explore the clinical indication and effect on the patients with type 2 diabetes mellitus (T2DM), a pilot clinical trial and metabolomics study were carried out. In the clinical study, T2DM patients were divided into three groups and treated with TZQ, placebo, or acarbose for 12 weeks, respectively. The metabolomic study based on UPLC Q-TOF MS was performed including patients with hypertriglyceridemia in TZQ and placebo groups and healthy volunteers. The clinical results showed that TZQ could reduce glycosylated hemoglobin (HbA1c) and fasting insulin. For patients with hypertriglyceridemia in TZQ group, the levels of HbA1c all decreased and were correlated with the baseline level of triglyceride. Metabonomics data showed a significant difference between patients and healthy volunteers, and 17 biomarkers were identified. After 12-week treatment with TZQ, 11 biomarkers decreased significantly (<0.05), suggesting that TZQ could improve the metabolomic abnormalities in these participants. In conclusion, the clinical indication of TZQ was T2DM with hypertriglyceridemia, and its target was related to glycerophospholipid metabolism.

Citing Articles

The reporting quality of randomized controlled trials in Chinese herbal medicine (CHM) formulas for diabetes based on the consort statement and its extension for CHM formulas.

Liu Y, Hu C, Zhou K, Zhang Y, Kang J, Wen Y Front Pharmacol. 2024; 15:1288479.

PMID: 38318135 PMC: 10839105. DOI: 10.3389/fphar.2024.1288479.

Integrated pyroptosis measurement and metabolomics to elucidate the effect and mechanism of tangzhiqing on atherosclerosis.

Chen R, Chen T, Zhou Z, Song Z, Feng W, Yang X Front Physiol. 2022; 13:937737.

PMID: 36171973 PMC: 9512057. DOI: 10.3389/fphys.2022.937737.

Identification of Insulin Resistance Biomarkers in Metabolic Syndrome Detected by UHPLC-ESI-QTOF-MS.

Oyoun Alsoud L, Soares N, Al-Hroub H, Mousa M, Kasabri V, Bulatova N Metabolites. 2022; 12(6).

PMID: 35736441 PMC: 9227428. DOI: 10.3390/metabo12060508.

Sanye Tablet Ameliorates Insulin Resistance and Dysregulated Lipid Metabolism in High-Fat Diet-Induced Obese Mice.

Yao M, Li L, Huang M, Tan Y, Shang Y, Meng X Front Pharmacol. 2021; 12:713750.

PMID: 34658856 PMC: 8511530. DOI: 10.3389/fphar.2021.713750.

Altering the inhibitory kinetics and molecular conformation of maltase by Tangzhiqing (TZQ), a natural α-glucosidase inhibitor.

Li Y, Zhang X, Wang R, Han L, Huang W, Shi H BMC Complement Med Ther. 2020; 20(1):350.

PMID: 33208112 PMC: 7672964. DOI: 10.1186/s12906-020-03156-3.

References

Yu D, Moore S, Matthews C, Xiang Y, Zhang X, Gao Y . Plasma metabolomic profiles in association with type 2 diabetes risk and prevalence in Chinese adults. Metabolomics. 2016; 12. PMC: 5102259. DOI: 10.1007/s11306-015-0890-8. View

Stancakova A, Civelek M, Saleem N, Soininen P, Kangas A, Cederberg H . Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012; 61(7):1895-902. PMC: 3379649. DOI: 10.2337/db11-1378. View

Yuhong H, Wenxu F, Yanfen L, Yu L, Ziqiang L, Liu Y . Comparison of the Effects of Acarbose and TZQ-F, a New Kind of Traditional Chinese Medicine to Treat Diabetes, Chinese Healthy Volunteers. Evid Based Complement Alternat Med. 2014; 2014:308126. PMC: 3997856. DOI: 10.1155/2014/308126. View

Gao J, Li J, An Y, Liu X, Qian Q, Wu Y . Increasing effect of Tangzhiqing formula on IRS-1-dependent PI3K/AKT signaling in muscle. BMC Complement Altern Med. 2014; 14:198. PMC: 4096524. DOI: 10.1186/1472-6882-14-198. View

Suhre K, Meisinger C, Doring A, Altmaier E, Belcredi P, Gieger C . Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One. 2010; 5(11):e13953. PMC: 2978704. DOI: 10.1371/journal.pone.0013953. View

Nan Xia J, Qin Zhang D, Du J, Wen J . Regulation effects of TZQ-F on adipocyte differentiation and insulin action. J Ethnopharmacol. 2013; 150(2):692-9. DOI: 10.1016/j.jep.2013.09.038. View

Selathurai A, Kowalski G, Burch M, Sepulveda P, Risis S, Lee-Young R . The CDP-Ethanolamine Pathway Regulates Skeletal Muscle Diacylglycerol Content and Mitochondrial Biogenesis without Altering Insulin Sensitivity. Cell Metab. 2015; 21(5):718-30. DOI: 10.1016/j.cmet.2015.04.001. View

Holden H, Rayment I, Thoden J . Structure and function of enzymes of the Leloir pathway for galactose metabolism. J Biol Chem. 2003; 278(45):43885-8. DOI: 10.1074/jbc.R300025200. View

Perry R, Samuel V, Petersen K, Shulman G . The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014; 510(7503):84-91. PMC: 4489847. DOI: 10.1038/nature13478. View

10.

Lu Y, Wang Y, Ong C, Subramaniam T, Choi H, Yuan J . Metabolic signatures and risk of type 2 diabetes in a Chinese population: an untargeted metabolomics study using both LC-MS and GC-MS. Diabetologia. 2016; 59(11):2349-2359. DOI: 10.1007/s00125-016-4069-2. View

11.

Rutterford C, Copas A, Eldridge S . Methods for sample size determination in cluster randomized trials. Int J Epidemiol. 2015; 44(3):1051-67. PMC: 4521133. DOI: 10.1093/ije/dyv113. View

12.

Rao U . Concepts in sample size determination. Indian J Dent Res. 2013; 23(5):660-4. DOI: 10.4103/0970-9290.107385. View

13.

Liu J, Semiz S, van der Lee S, van der Spek A, Verhoeven A, van Klinken J . Metabolomics based markers predict type 2 diabetes in a 14-year follow-up study. Metabolomics. 2017; 13(9):104. PMC: 5533833. DOI: 10.1007/s11306-017-1239-2. View

14.

Han M, Lim Y, Quan W, Kim J, Chung K, Kang M . Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance. J Lipid Res. 2011; 52(6):1234-1246. PMC: 3090244. DOI: 10.1194/jlr.M014787. View

15.

Dreyfus H, Urban P, EDEL-HARTH S, Neskovic N, Mandel P . Enzymatic synthesis of glucocerebroside by UDP-glucose: ceramide glucosyltransferase during ontogenesis of chicken retina. Lipids. 1975; 10(9):545-7. DOI: 10.1007/BF02532358. View

16.

Gorska M, Dobrzyn A, Baranowski M . Concentrations of sphingosine and sphinganine in plasma of patients with type 2 diabetes. Med Sci Monit. 2004; 11(1):CR35-8. View

17.

Li Y, Ge M, Ciani L, Kuriakose G, Westover E, Dura M . Enrichment of endoplasmic reticulum with cholesterol inhibits sarcoplasmic-endoplasmic reticulum calcium ATPase-2b activity in parallel with increased order of membrane lipids: implications for depletion of endoplasmic reticulum calcium stores and.... J Biol Chem. 2004; 279(35):37030-9. DOI: 10.1074/jbc.M405195200. View

18.

Tenenbaum A, Klempfner R, Fisman E . Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014; 13:159. PMC: 4264548. DOI: 10.1186/s12933-014-0159-y. View

19.

An Y, Liu X, Qian Q, Zhang D, Li Y, Gao X . Triglyceride accumulation: inhibitory effects of tangzhiqing formula. Altern Ther Health Med. 2013; 19(5):20-9. View

20.

Floegel A, Stefan N, Yu Z, Muhlenbruch K, Drogan D, Joost H . Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2012; 62(2):639-48. PMC: 3554384. DOI: 10.2337/db12-0495. View